*Applications will be reviewed on a rolling-basis.
MUST APPLY THROUGH EXTERNAL LINK.
A research opportunity is currently available with the Office of Blood Research and Review (OBRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) located in Silver Spring, Maryland.
Under the guidance of a mentor, the participant will receive training and contribute to studies to develop and optimize molecular assays for virus detection and quantification. The participant will have the opportunity to contribute to the development of reference panels for SARS-CoV-2 and emerging viruses to aid standardization of diagnostic tests between different laboratories. The participant will receive training in molecular virology and cell biology methods including virus propagation in cell culture, virus detection and quantification, infectivity assays, virus purification and biochemical characterization, genetic sequencing, sequence analysis, RT-qPCR, and data analysis.
Anticipated Appointment Start Date: September 1, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
The qualified candidate should have received a bachelor’s or master’s degree in one of the relevant fields, or be currently pursuing one of the degrees and will reach completion by the appointment start date. Degree must have been received within five years of the appointment start date.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0041) in your email.